GPX4 and acute myeloid leukemia: We found that combined administration of ML385 and GPX4 inhibitor markedly inhibits the proliferation of AML cell lines compared with either inhibitor alone, and the combination index (CI) indicating that these two inhibitors have synergistic effects (Fig. 3c and d and S4a).